Clinical trial NCT06804408: Unpacking the "Mind" and "Body" Pathways of the Antidepressant Effect of Qigong in Older Adults: A Pilot Study
Official title: Unpacking the "Mind" and "Body" Pathways of the Antidepressant Effect of Qigong in Older Adults: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Qigong
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2025-02-03
Enrollment: 106
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goals of the study are to explore the neurobiological mechanisms and cognitive benefits of qigong in older adults. The main research questions are:

* Does 12-week qigong training lead to significant enhancement in serum adiponectin, serum BDNF and significant reduction in salivary cortisol?
* Does 12-week qigong training bring significant improvement in global cognitive function?

Participants are older adults aged 60 or above. They were randomly assigned to qigong training, mindfulness training, physical exercise training, or wait-list which all last for 12 weeks. Their changes before and after the 12-week period in depressive symptoms, neurobiological markers, and cognitive functions are assessed.


Eligibility criteria: Inclusion Criteria:

* 60 years or older;
* With mild or severer levels of depressive symptoms as indicated by the Geriatric Depression Scale (GDS-8) scores of 5 or above, or Depression Anxiety and Stress Scale-21 (DASS-21) depression subscale scores of 4 or above
* Self-identified as physically stable and without life-threatening diseases.

Exclusion Criteria:

* With a history of practicing or receiving training of any form of mind-body or regular exercises (including tai chi, yoga, and qigong, or regular physical activity \> 3 times/week) during the month prior to study enrollment
* Having changed medications or the dose of medications prescribed for their health condition in the month prior to study enrollment
* With severe cognitive or language impairment as defined as a score of less than 21 on Montreal Cognitive Assessment (MoCA-5min)
* Undergoing electroconvulsive therapy, psychotherapy, or psychoeducation for a psychological or psychiatric condition
* Unable to demonstrate satisfactory standing balance.

Primary outcomes:
measure: Depressive symptoms
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Global cognitive function
timeFrame: Baseline and post-intervention (12 weeks after baseline)
Secondary outcomes:
measure: Serum adiponectin
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Serum BDNF
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Salivary cortisol
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Attention
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Inhibitory control
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: Working memory
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: ERP N2 amplitude
timeFrame: Baseline and post-intervention (12 weeks after baseline)
measure: ERP P3 amplitude
timeFrame: Baseline and post-intervention (12 weeks after baseline)
Other outcomes:
Locations:
city: Kowloon
country: Hong Kong
facility: Hong Kong Polytechnic University, Department of Rehabilitation Sciences
Study officials:
References: